Here are 1-3 brief analogies for Recursion Pharmaceuticals (RXRX):

• Amazon for drug discovery
• Google for decoding biology

• REC-994: A drug candidate in Phase IIa clinical trial for treating cerebral cavernous malformation.
• REC-2282: A drug candidate for the treatment of neurofibromatosis type 2.
• REC-4881: A drug candidate to treat familial adenomatous polyposis.
• REC-3599: A drug candidate in Phase I clinical trial for treating GM2 gangliosidosis.
• REC-3964: A preclinical stage drug candidate to treat Clostridium difficile colitis.
• REC-64917: A preclinical stage drug candidate for the treatment of neural or systemic inflammation.
• REC-65029: A preclinical stage drug candidate to treat HRD-negative ovarian cancer.
• REC-648918: A preclinical stage drug candidate designed to enhance anti-tumor immune response.
• REC-2029: A preclinical stage drug candidate for the treatment of wnt-mutant hepatocellular carcinoma.
• REC-14221: A preclinical stage drug candidate to treat solid and hematological malignancies.
• REC-64151: A preclinical stage drug candidate for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer.

Recursion Pharmaceuticals (RXRX) operates as a clinical-stage biotechnology company focused on drug discovery and development. Given the nature of its business, which involves developing drug candidates and technological platforms for drug discovery, the company primarily sells to other companies and institutions through collaborations and agreements rather than directly to individuals.

Based on the provided information, the major customer companies (or strategic partners acting in a customer-like capacity for its technology and drug candidates) include:

• Bayer AG (OTCMKTS: BAYRY)
• Takeda Pharmaceutical Company Limited (NYSE: TAK)

Najat Khan, Ph.D. CEO and President

Dr. Najat Khan assumed the role of CEO and President of Recursion Pharmaceuticals on January 1, 2026. She brings deep expertise from the pharmaceutical and healthcare industry, integrating scientific discovery, data, technology, and business strategy. Prior to becoming CEO, Dr. Khan served as Recursion's Chief R&D and Commercial Officer and was instrumental in advancing multiple clinical programs and leading the company's combination with Exscientia. Before joining Recursion in 2024, she was the Chief Data Science Officer and Senior Vice President at Johnson & Johnson Innovative Medicine.

Ben Taylor Chief Financial Officer & President Recursion UK

Ben Taylor was appointed Chief Financial Officer (and President Recursion UK) effective November 20, 2024, following Recursion's acquisition of Exscientia. He previously served for over four years as the CFO of Exscientia. Mr. Taylor has more than two decades of experience in healthcare investment banking and executive roles, including 15 years at Goldman Sachs and Barclays, where he focused on financing, strategic, and cross-border transactions in the biopharmaceutical industry across the U.S., Asia, and Europe. He also served as President and CFO for Tyme Technologies, a NASDAQ-listed oncology-focused biotechnology company, guiding its advancement from Phase 1 to Phase 3. Before Exscientia, he was interim CFO at Aetion, a healthtech company.

Chris Gibson, Ph.D. Co-Founder and Board Chair

Dr. Chris Gibson co-founded Recursion Pharmaceuticals in 2013 and served as its CEO from founding through 2025, building it into a publicly listed TechBio company. He is now the Co-Founder and Board Chair. Dr. Gibson developed the foundational technology for Recursion during his MD/PhD studies in Dr. Dean Li's lab at the University of Utah. He holds undergraduate degrees in bioengineering and management from Rice University. Dr. Gibson is active as an advisor and mentor to emerging biotech founders.

Tina Larson Chief Operating Officer

Tina Larson is the Chief Operating Officer at Recursion Pharmaceuticals, a role she assumed in 2018. In this position, she oversees technical operations, including the company’s automated screening platform, and core business functions. Prior to joining Recursion, Ms. Larson was the Senior Vice President of Technical Operations at Achaogen, where she established their Technical Operations organization. She also spent 20 years at Genentech and Roche, holding leadership positions in Technical Development, Manufacturing, and Engineering, and contributed to every commercial biopharmaceutical product launched from Genentech during her tenure.

David Hallett, Ph.D. Chief Scientific Officer

Dr. David Hallett serves as the Chief Scientific Officer at Recursion. He joined Recursion following approximately five years as the Chief Scientific Officer and Interim CEO of Exscientia. Dr. Hallett is an experienced "drug hunter" with over two decades of experience leading scientific teams and driving strategic collaborations in the pharmaceutical and biotechnology industries. Before Exscientia, from 2005 to 2019, he held various positions at Evotec, including Executive Vice President of Chemistry and EVP of Alliance Management. He also served as a Research Fellow at Merck & Co., Inc.

1. Clinical Trial Failure and Regulatory Approval Risk: As a clinical-stage biotechnology company, Recursion Pharmaceuticals' success is heavily dependent on its drug candidates successfully progressing through various phases of clinical trials and ultimately receiving regulatory approval. The company has multiple programs in Phase I and Phase IIa clinical trials, and many more in preclinical stages. A failure in any of these stages due to lack of efficacy, unexpected side effects, or an inability to meet regulatory requirements could significantly delay or terminate the development of a drug, leading to substantial financial losses and a negative impact on the company's prospects.
2. Significant Capital Requirements and Funding Risk: Developing and bringing a new drug to market is an extremely capital-intensive process, especially for a company with multiple drug candidates in various stages of development. Recursion Pharmaceuticals, as a clinical-stage entity, is likely to incur substantial research and development expenses without significant product revenue. The company may need to raise additional capital through equity offerings, debt financing, or strategic partnerships, which could dilute existing shareholders or be difficult to secure on favorable terms, posing a risk to its ability to fund ongoing operations and future development.
3. Competition and Intellectual Property Risk: The biotechnology and pharmaceutical industries are highly competitive. Recursion Pharmaceuticals' drug candidates could face competition from other companies developing similar treatments for the same diseases, potentially through different mechanisms or more advanced stages of development. Furthermore, the company's ability to protect its proprietary technology and drug candidates through patents and other intellectual property rights is crucial. Any challenges to its intellectual property, inability to obtain new patents, or expiration of existing patents could negatively impact its competitive position and future revenue potential.

The addressable markets for Recursion Pharmaceuticals' main products are as follows:

• REC-994 (Cerebral Cavernous Malformation): The global cerebral cavernous malformation market was valued at USD 415.63 million in 2024 and is projected to reach USD 628.25 million by 2032, growing at a compound annual growth rate (CAGR) of 5.3% during the forecast period. North America holds the largest share of this market, with the U.S. accounting for a significant portion within North America.
• REC-2282 (Neurofibromatosis Type 2): The Neurofibromatosis Type-2 market in the G-8 region was valued at USD 188.09 million in 2020. The United States accounts for the highest market size for Neurofibromatosis Type-2 compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain), Japan, and China. The Neurofibromatosis Type 2 market in the 7MM (United States, EU4, the UK, and Japan) is anticipated to experience steady growth with a robust CAGR from 2024 to 2034.
• REC-4881 (Familial Adenomatous Polyposis): The global familial adenomatous polyposis treatment market size was valued at USD 2.09 billion in 2024 and is expected to reach USD 6.42 billion by 2032, at a CAGR of 15.00%. North America was the largest region in the familial adenomatous polyposis (FAP) treatment market in 2025, with the U.S. capturing 82% of the revenue share within North America in 2024.
• REC-3599 (GM2 Gangliosidosis): The global GM2 gangliosidosis market is projected to reach an estimated value of USD 270 million in 2024 and is expected to grow to approximately USD 720 million by 2034, exhibiting a strong CAGR of around 10.5% during this period. North America is expected to dominate the GM2 gangliosidosis market.

Recursion Pharmaceuticals (NASDAQ: RXRX) is poised for future revenue growth over the next 2-3 years, driven primarily by its strategic collaborations, the advancement of its wholly-owned clinical pipeline, and the continued expansion and validation of its AI-driven drug discovery platform.

Drivers of Future Revenue Growth:

1. Continued Milestone Payments from Strategic Collaborations: Recursion Pharmaceuticals has established significant partnerships with pharmaceutical giants like Sanofi and Roche/Genentech. Revenue from these collaborations, largely through milestone payments, has been a key driver of the company's financial performance. For instance, Recursion's Q4 2025 revenue was significantly bolstered by milestone payments from both Roche/Genentech and Sanofi. The Sanofi collaboration has already generated $134 million ($100 million upfront and $34 million in milestones), with expectations for further later-stage discovery milestones over the next 18 months. Similarly, the partnership with Roche and Genentech has yielded $213 million in upfront and milestone payments to date, with potential for additional upcoming milestones. Analysts are forecasting a significant acceleration in revenue for Recursion, with collaboration milestones being a primary income source.

2. Advancement of the Wholly-Owned Clinical Pipeline: The progression of Recursion's internal drug candidates through clinical trials is expected to generate significant value and potential future revenue. The company currently has five differentiated clinical programs advancing with defined next-stage milestones. A notable example is REC-4881, a program for Familial Adenomatous Polyposis (FAP), which has demonstrated positive Phase 2 proof of concept with a 43% median reduction in polyp burden in patients. Recursion plans to engage with the FDA in the first half of 2026 to discuss a registration pathway for REC-4881, and additional data is anticipated in early 2027. Other pipeline assets, such as RBM39, CDK7, ENPP1, MALT1, and LSD1, also have upcoming catalysts including early safety and pharmacokinetic data or go/no-go decisions expected within the next 18-24 months. The successful advancement of these programs could lead to further milestone payments, licensing deals, or, in the longer term, product sales.

3. Expansion and Validation of the AI-Driven Drug Discovery Platform: Recursion's proprietary AI-driven drug discovery platform, the "Recursion OS," is a core asset that continually drives new opportunities for revenue growth. The company is at an "important inflection point" in translating its platform's insights into tangible evidence for generating effective medicines. The acquisition of Exscientia in November 2024 has further strengthened Recursion's capabilities by integrating AI-enabled chemistry and molecular design into its existing phenomics platform. This enhanced platform is expected to attract new partnerships and expand existing collaborations, leading to additional upfront payments and milestone revenues. Management has emphasized a strategic focus on scaling generative drug design and applying AI across the full life cycle of R&D, positioning the company as a leader in AI-native drug discovery.

Capital Allocation Decisions (Last 3-5 Years)

Share Issuance

• Recursion Pharmaceuticals significantly increased its outstanding shares from 0.169 billion in December 2021 to 0.447 billion in December 2025, indicating substantial share issuance.
• The company bolstered its cash position through multiple equity raises and an At-The-Market (ATM) equity program, including an offering in June 2024.
• Recursion secured a new $500 million ATM offering agreement with Citigroup in February 2025.

Inbound Investments

• Recursion has received over $500 million in cumulative upfront and progress-based milestone payments from strategic partners as of February 2026.
• This includes $213 million in cash inflows from its collaboration with Roche and Genentech, and $134 million from its partnership with Sanofi.
• A transformational collaboration with Roche and Genentech was announced in December 2021 to advance up to 40 novel potential medicines in neuroscience and gastrointestinal oncology, and the collaboration with Bayer was expanded in 2021 to include more than a dozen fibrosis programs.

Outbound Investments

• In November 2024, Recursion Pharmaceuticals completed the acquisition of Exscientia plc for $630.1 million, a move aimed at strengthening its AI-enabled drug discovery capabilities. This was identified as the largest merger or acquisition in the TechBio space to date.

Capital Expenditures

• Capital expenditures were reported as $3.91 million in 2025 and $6.5 million in fiscal year 2024.
• Investments have primarily focused on building out the Recursion Operating System (OS), including scaling transcriptomic technologies, enhancing hiPSC-derived cell production, and integrating in-house chemistry capabilities.
• In late 2023, the company announced an expansion of its BioHive-1 supercomputer with NVIDIA, with the goal of making it the fastest supercomputer wholly owned and operated by any biopharma company.